Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis | Zendy

Kazufumi Dohmen | Zendy; Shin-ya Onohara | Zendy; Shigeru Harada | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis

Author(s) -

Kazufumi Dohmen,

Shin-ya Onohara,

Shigeru Harada

Publication year - 2021

Publication title -

korean journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.203

H-Index - 25

eISSN - 2233-6869

pISSN - 1598-9992

DOI - 10.4166/kjg.2021.092

Subject(s) - fenofibrate , medicine , asymptomatic , gastroenterology

The addition of a fibrate to ursodeoxycholic acid (UDCA) is the standard treatment for asymptomatic primary biliary cholangitis (aPBC) with an incomplete response to UDCA. Among the fibrates, bezafibrate and fenofibrate increase the serum creatinine level and reduce the estimated glomerular filtration rate (eGFR). Pemafibrate is an selective peroxisome proliferator-activated receptor alpha modulator (SPPARM-α) mainly metabolized by the liver that was recently approved to treat dyslipidemia. This study confirmed the changes in the biochemical markers after switching from fenofibrate to pemafibrate in aPBC patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research